NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year
Capsida will also present data from its potential best-in-class programs for Parkinson’s disease associated with GBA mutations (CAP-003 PD-GBA) and Friedreich’s ataxia (CAP-004), as well as capsid engineering and manufacturing
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25.
Neuron23 today announced the publication of a manuscript in the Proceedings of the National Academy of Sciences (PNAS), which explores the role of tyrosine kinase 2 (TYK2) inhibition in neuroinflammation, microglia and astrocyte regulation, and modulation of various biomarkers of neuroinflammation in Experimental Autoimmune Encephalomyelitis (EAE), a widely utilized model of multiple sclerosis (MS) and neuroinflammation.
Data from the Phase 1 healthy volunteer study of NEU-411 will be presented at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), taking place April 1-5 in Vienna.
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million
